CA3109285A1 - Crystalline forms of therapeutic compounds and uses thereof - Google Patents

Crystalline forms of therapeutic compounds and uses thereof

Info

Publication number
CA3109285A1
CA3109285A1 CA3109285A CA3109285A CA3109285A1 CA 3109285 A1 CA3109285 A1 CA 3109285A1 CA 3109285 A CA3109285 A CA 3109285A CA 3109285 A CA3109285 A CA 3109285A CA 3109285 A1 CA3109285 A1 CA 3109285A1
Authority
CA
Canada
Prior art keywords
less
equal
crystalline
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3109285A
Other languages
English (en)
French (fr)
Inventor
Elizabeth ENLOW
Minh Ngoc Nguyen
Winston Z. ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/184,886 external-priority patent/US9353123B2/en
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of CA3109285A1 publication Critical patent/CA3109285A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA3109285A 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof Abandoned CA3109285A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US61/898,741 2013-11-01
US14/184,886 US9353123B2 (en) 2013-02-20 2014-02-20 Therapeutic compounds and uses thereof
US14/184,886 2014-02-20
CA2928665A CA2928665A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2928665A Division CA2928665A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3109285A1 true CA3109285A1 (en) 2015-05-07

Family

ID=53005242

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3109285A Abandoned CA3109285A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof
CA2928665A Abandoned CA2928665A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2928665A Abandoned CA2928665A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Country Status (5)

Country Link
EP (1) EP3062795A4 (https=)
JP (2) JP6426195B2 (https=)
AU (1) AU2014341966B2 (https=)
CA (2) CA3109285A1 (https=)
WO (1) WO2015066584A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3062795A4 (en) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP7108681B2 (ja) 2017-08-11 2022-07-28 アモーレパシフィック コーポレーション （ｒ）‐ｎ‐［１‐（３，５‐ジフルオロ‐４‐メタンスルホニルアミノ‐フェニル）‐エチル］‐３‐（２‐プロピル‐６‐トリフルオロメチル‐ピリジン‐３‐イル）‐アクリルアミドを含む医薬組成物
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
WO2020179837A1 (en) 2019-03-04 2020-09-10 Ricoh Company, Ltd. Cooperation processing apparatus and method
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
JP4608215B2 (ja) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
JP2016510000A (ja) * 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
EP3062795A4 (en) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
EP3062795A4 (en) 2017-05-31
AU2014341966A1 (en) 2016-05-12
AU2014341966B2 (en) 2017-08-17
JP6426195B2 (ja) 2018-11-21
JP2019038824A (ja) 2019-03-14
EP3062795A1 (en) 2016-09-07
JP2016535779A (ja) 2016-11-17
WO2015066584A1 (en) 2015-05-07
CA2928665A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
US11713323B2 (en) Crystalline forms of therapeutic compounds and uses thereof
CA2871748C (en) Pharmaceutical nanoparticles showing improved mucosal transport
US9688688B2 (en) Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2019038824A (ja) 治療用化合物の結晶形態及びその使用
CA2914815A1 (en) Urea derivatives and uses thereof
US9890173B2 (en) Crystalline forms of therapeutic compounds and uses thereof
AU2014275198B2 (en) Novel compounds and uses thereof
HK1228197B (en) Crystalline forms of therapeutic compounds and uses thereof
HK1228197A1 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210216

FZDE Discontinued

Effective date: 20230808